Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Aethlon Medical Inc. ($AEMD) announced the results of its study seeking to validated the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The results validated the ability of the Aethlon Hemopurifier® to capture latent viral pathogens that are associated with increased mortality in immune-suppressed sepsis patients and also contribute to organ rejection in transplant patients.
Aethlon stock has shown choppy performance in the recent past and the stock is currently trading nearly 50 percent below its 52 weeks high of $9.09. The price is likely to pick up in response to its positive test news.

Peregrine Pharmaceuticals Inc. ($PPHM) stock has shown robust performance in last couple of days as its price spiked over 10 percent in the Wednesday trading session. The company had recently announced that its exosome-based cancer detection technology reported concrete results in early studies. The system makes clear distinction between healthy individuals and patients with ovarian tumors. the examination of PS-positive exosome levels also allows for distinguishing between benign and malignant tumors.
The company stock has gained over 71 percent this year so far. Peregrine had licensed exosome-based cancer diagnostic technology from the University of Texas Southwestern Medical Center in July 2016. The company aims to build a reliable test for further clinical testing and is seeking a strategic partner.

 

• HTG Molecular Diagnostics ($HTGM) reported receiving a notice from NASDAQ informing the company that its stock would be delisted on February 23 due to its inability to regain listing requirements related to minimum stockholders' equity of $10 million. The company has appealed the decision and requested a hearing to address the situation. Delisting will be stayed until the Nasdaq Hearings Panel renders a decision.
• Amphastar Pharmaceuticals ($AMPH) reported that the FDA has rejected its New Drug Application (NDA) seeking approval of Naloxone Hydrochloride 2 mg/0.5 mL Nasal Spray for the emergency treatment of opioid overdose. The Complete Response Letter (CRL) noted the need for a human factors study, device evaluation and other items before the application can be approved. The company plans continue offering naloxone in pre-filled syringes.

• Luminex Corporation ($LMNX) reported that its board of directors has authorized the initiation of a quarterly cash dividend to its shareholders, the first in the company's history. This initial cash dividend will be payable on April 14, 2017. The record date for this purpose is as of the close of business on March 24, 2017. The board of directors intends for the Company to pay a regular quarterly cash dividend of $0.06 to holders of its common stock, representing a planned annual dividend of $0.24 per share.
• Celgene ($CELG) announced that it has received the FDA approval for expanding the existing indication for REVLIMID (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). REVLIMID is now the first and only treatment to receive FDA approval for maintenance use following auto-HSCT. The label was earlier expanded by the FDA in February, 2015 to include patients with newly diagnosed MM.

 
• United Therapeutics Corporation ($UTHR) announced its net revenue for the financial year 2016 at $1.6 billion, up $133 million. Its net earnings for the same time period stood at $700 million. For the fourth quarter of the year, the company’s net revenue stood at $409 million, up $4.1 million from the corresponding quarter of the previous year. Its net income for the quarter was reported at $4.12 per share.
• NeoGenomics ($NEO) reported its fourth quarter loss at $6.2 million. On per share basis, the net loss stood at $0.05. The market experts were expecting the earnings of $0.03 per share. The company announced its quarterly revenue at $60.5 million, lagging behind consensus estimate of $61.5 million in revenue. For the entire year, the company’s loss widened to $5.7 million, or $0.39 per share. NeoGenomics’ revenue was reported as $244.1 million.

Brokerage Action Company Rating Price Target
BTIG Research Reiterates Cerus Corporation (CERS)
Buy $8.00
Credit Suisse Group Raises Target Clovis Oncology (CLVS)
$70.00
Morgan Stanley Raises Target Clovis Oncology (CLVS)
$72.00
Piper Jaffray Companies Reiterates Intra-Cellular Therapies (ITCI)
Overweight $22.00

Gainers (% price change) Last Trade Change Mkt Cap
Depomed Inc
DEPO (NASDAQ)
17.25 +1.48 (9.38%) 1.02B
BioDelivery Sciences Intl
BDSI (NASDAQ)
2.05 +0.15 (7.89%) 112.42M
Insys Therapeutics Inc
INSY (NASDAQ)
13.48 +0.83 (6.56%) 1.10B
Repligen Corporation
RGEN (NASDAQ) 32.32 +1.84 (6.04%) 1.07B
Sarepta Therapeutics Inc
SRPT (NASDAQ)
30.38 +1.70 (5.93%) 1.68B
Losers (% price change)
United Therapeutics Corp.
UTHR (NASDAQ)
146.98 -20.94 (-12.47%) 6.23B
Oclaro, Inc.
OCLR (NASDAQ)
9.72 -1.25 (-11.39%) 1.61B
LeMaitre Vascular Inc
LMAT (NASDAQ)
22.16 -2.43 (-9.88%) 425.49M
Osiris Therapeutics, Inc.
OSIR (NASDAQ)
5.47 -0.40 (-6.81%) 183.76M
Sangamo Therapeutics Inc
SGMO (NASDAQ) 3.70 -0.25 (-6.33%) 258.04M
Most Actives (dollar volume)
Bristol-Myers Squibb Co
BMY (NYSE)
55.35 +0.57 (1.04%) 92.82B
Pfizer Inc.
PFE (NYSE)
33.59 -0.03 (-0.09%) 203.84B
Gilead Sciences, Inc.
GILD (NASDAQ)
68.83 -0.46 (-0.66%) 89.95B
Johnson & Johnson
JNJ (NYSE)
119.52 -0.14 (-0.12%) 327.35B
Merck & Co., Inc.
MRK (NYSE)
65.29 -0.19 (-0.29%) 180.26B